Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

vTv Therapeutics (VTVT) Non-Current Debt (2016 - 2023)

vTv Therapeutics' Non-Current Debt history spans 10 years, with the latest figure at $922000.0 for Q1 2023.

  • For Q1 2023, Non-Current Debt rose 19.74% year-over-year to $922000.0; the TTM value through Mar 2023 reached $922000.0, up 19.74%, while the annual FY2022 figure was $684000.0, 45.8% down from the prior year.
  • Non-Current Debt for Q1 2023 was $922000.0 at vTv Therapeutics, up from $684000.0 in the prior quarter.
  • Across five years, Non-Current Debt topped out at $4.5 million in Q1 2021 and bottomed at $684000.0 in Q4 2022.
  • The 5-year median for Non-Current Debt is $2.3 million (2021), against an average of $2.3 million.
  • The largest annual shift saw Non-Current Debt skyrocketed 987.06% in 2019 before it crashed 82.96% in 2022.
  • A 5-year view of Non-Current Debt shows it stood at $2.6 million in 2019, then grew by 10.38% to $2.9 million in 2020, then tumbled by 56.04% to $1.3 million in 2021, then crashed by 45.8% to $684000.0 in 2022, then surged by 34.8% to $922000.0 in 2023.
  • Per Business Quant, the three most recent readings for VTVT's Non-Current Debt are $922000.0 (Q1 2023), $684000.0 (Q4 2022), and $1.4 million (Q3 2022).